Salivary proteome in Parkinson’s disease
Objective: The purpose of this paper is to characterize salivary proteome in PD comparing to healthy subjects using proteomic approach. Background: Parkinson’s disease (PD) is…Feasibility of Studying the PD Microbiome in Frozen Saliva and Formalin-Fixed Colon From the Systemic Synuclein Sampling Study (S4)
Objective: To examine feasibility of obtaining microbiome data from frozen saliva and formalin-fixed, paraffin-embedded (FFPE) colon specimens. Background: The gastrointestinal tract microbiome is of great…Microglial activation associated with a faster progression of nigrostriatal dysfunction in patients with isolated REM sleep behavior disorder
Objective: To assess the role of early microglial activation on the progression of nigrostriatal dysfunction, measured with 18F-DOPA PET, in isolated REM sleep behavior disorder…Regional free-water differentially associated with glial activation, neuroinflammation, and neurodegeneration in de novo Parkinson’s disease
Objective: Assess to what extent free-water(FW) as measured by diffusion-weighted MRI(dMRI) is a neuroimaging marker of glial activation, neuroinflammation, and neurodegeneration in de novo Parkinson’s disease(PD) patients from…CSF inflammatory cytokines and correlation with clinical features in early, untreated PD patients
Objective: The aims of the present study were to investigate the levels of inflammatory cytokines in the cerebrospinal fluid (CSF) of drug-naïve Parkinson's Disease (PD)…Disease progression characterized by motor performance, dopaminergic neurodegeneration and T cell infiltration in the transgenic hm2-α-SYN-39 mouse model of Parkinson´s disease
Objective: To study disease progression in the transgenic (tg) hm2-α-SYN-39 mouse model of Parkinson´s disease (PD) by assessment of motor performance, dopaminergic neurodegeneration and T…A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of AKST4290 in Subjects with Parkinson’s Disease on Stable Dopaminergic Treatment (TEAL Study)
Objective: Assessment of efficacy and safety in subjects with Parkinson’s disease (PD) following treatment for 12 weeks with placebo or AKST4290, a highly specific and…Allogeneic bone marrow-derived mesenchymal stem cells safety and tolerability in idiopathic Parkinson’s disease
Objective: Prove safety and feasibility of delivering allogeneic bone marrow-derived mesenchymal stem cells (MSC) intravenously in escalated doses to patients with idiopathic Parkinson’s disease (PD).…Development and validation of a profile of peripheral immune biomarkers for Parkinson’s disease: A multicenter, retrospective study
Objective: This multicenter study was designed to investigate the association between multiple peripheral immune biomarkers and the risk of Parkinson’s disease (PD). Background: Several studies…Predicting the effects of Tumor Necrosis Factor inhibition on the risk and age at onset of Parkinson’s disease: A Mendelian randomization study
Objective: To evaluate whether inhibition of Tumor Necrosis Factor (TNF) signaling may reduce the risk of Parkinson’s disease (PD) and/or delay onset of PD. Background:…
- « Previous Page
- 1
- …
- 10
- 11
- 12
- 13
- 14
- …
- 22
- Next Page »